Latest News
BridgeBio Pharma, Inc.
- BridgeBio Pharma will report Q3 2026 results and issue business update: Can BBIO break above $69?
- BridgeBio Pharma (NDQ:BBIO): 5 Years From A Near-Death Experience, Its Has A Cumulative Opportunity Of ~$30bn At Its Fingertips!
- BridgeBio: Maintaining 'Strong Buy' Additional Encaleret Data ADH1 And Three Expected FDA Reviews
- BridgeBio Pharma (BBIO) Reports Positive Phase 3 Trial Results f
- BridgeBio Pharma (BBIO) Reports Positive Phase 3 Trial Results f
- BridgeBio presents encaleret trial data, doses first patient
- RBC Capital Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)
- BridgeBio Pharma stock rating reiterated at Buy by Canaccord
- FDA Grants Priority Review for BridgeBio Pharma's Oral Infigrati
- FDA accepts BridgeBio’s infigratinib NDA for achondroplasia By Investing.com
- Jefferies reiterates Buy on BridgeBio Pharma stock, $110 target
- BridgeBio Pharma xStock (BBIOX) Price Prediction for 2026 to 2031
Headlines from the last 30 days, linking to the original publishers. See all market news →